Biologically grounded AI that reads the whole biology of a tumor - and turns it into a treatment decision.
Two patients can share the same diagnosis and carry completely different tumors. BostonGene was built around that inconvenient fact - and around the idea that the biology hiding inside a tumor should shape the treatment, not just the label on the chart.
Founded in 2015 in Waltham, Massachusetts, BostonGene is a biotechnology company that applies computational biology and artificial intelligence to cancer. Its flagship, the Tumor Portrait test, folds DNA and RNA sequencing, tumor mutational burden, PD-L1 expression, gene signatures and tumor-microenvironment subtyping into a single, end-to-end assay. The company describes it, plainly, as a tumor "personality" test.
The point of that framing is not marketing. Most genomic cancer tests read mutations - the things that are broken in a tumor's DNA. BostonGene reads those too, but it also reads the RNA that shows which genes are actually switched on, and it profiles the immune cells and microenvironment surrounding the tumor. That surrounding biology often decides whether a therapy can even reach its target.
The result is a report meant to be acted on. Rather than handing an oncologist a raw list of variants, the platform produces a roadmap: which biomarkers are present, how the immune landscape looks, and which therapies the biology points toward for a patient with an advanced solid tumor.
The same engine runs in the other direction for drug developers. Pharmaceutical partners use BostonGene's molecular and immune profiling to find biomarkers, select the right patients for trials, and stratify populations - the unglamorous work that separates a trial that reads out cleanly from one that fails on the wrong cohort.
BostonGene sells to two audiences at once: oncology providers who order tests for patients, and pharmaceutical companies that use the platform to build better drugs. The building blocks are shared.
A tumor-normal assay integrating DNA and RNA sequencing with tumor mutational burden, PD-L1, gene signatures and microenvironment subtyping - a multimodal view of each tumor in one test.
The AI engine that decodes a patient's molecular profile, immune system and tumor microenvironment to surface disease drivers and potential drug targets.
Biomarker discovery, patient stratification and clinical-trial optimization for pharma partners, built on the same profiling stack.
Multiplex immunofluorescence imaging, flow cytometry and spatial analysis characterizing the tumor immune microenvironment.
Oncology has more therapies than ever - targeted drugs, immunotherapies, combinations. The hard part is matching them to the right patient. Guess wrong and a patient loses time they may not have.
BostonGene's answer is comprehensiveness. By profiling genome, transcriptome, immune cells and microenvironment together, it aims to close the gap between knowing what a tumor is and knowing what to do about it. For drug developers, the same completeness attacks the industry's most expensive failure mode: trials that enroll the wrong patients and read out inconclusive.
Precision oncology is competitive - Tempus AI, Caris Life Sciences, Foundation Medicine, Guardant Health, SOPHiA GENETICS and Personalis all work adjacent ground. BostonGene's edge is not more sequencing volume; it is the interpretive layer on top, and specifically its focus on the immune microenvironment that many genomics-first players treat as secondary.
BostonGene operates a B2B2C model. On the clinical side, oncologists and health systems order the Tumor Portrait test for patients with advanced solid tumors, generating diagnostic testing revenue. On the research side, pharmaceutical and biotech companies pay for molecular and immune profiling, biomarker discovery and trial services. The two feed each other - clinical data sharpens the platform, and the platform makes the clinical product more useful. Apollo estimates annual revenue near $63M.
The Tumor Portrait test serves as a roadmap to guide treatment decision-making - a tumor "personality" test.
BostonGene's platform combines deep biological insights with advanced AI to enable better therapeutic design and patient selection.
BostonGene has raised capital across a strategic investment and two priced rounds, reaching a valuation above $1 billion in 2022. Bars scaled to round size.
Lead investors: SoftBank Vision Fund 2 (Series A); NEC Corporation, Impact Investment Capital, Japan Industrial Partners (Series B).
Andrew Feinberg co-founds the company in Waltham, Massachusetts to apply computational biology to cancer.
NEC puts in $50M and forms a research collaboration; Andrew Feinberg becomes President & CEO.
SoftBank Vision Fund 2 leads the company's Series A financing.
BostonGene and NEC announce a partnership to offer Tumor Portrait tests internationally.
A $150M Series B led by NEC values the company at over $1 billion.
A landmark study provides clinical and analytical validation for the multimodal RNA and DNA assay.
Collaborations with AstraZeneca and Ottimo Pharma; Frost & Sullivan innovation recognition in AI-driven precision oncology.
The names that trust BostonGene with tumor data say as much as any pitch deck.
Early $50M strategic backer and global partner; joint venture to bring Tumor Portrait to Japan and other Asian markets.
Strategic collaboration on foundation-model-driven oncology and a co-developed small cell lung cancer assay.
Co-developed a small cell lung cancer assay now in a national study and on track toward standard of care.
Collaboration to accelerate a first-in-class PD-1/VEGFR2 immuno-oncology therapy using AI.
Andrew Feinberg - Co-founder, President & CEO
Feinberg co-founded BostonGene in 2015 and stepped into the President & CEO role in 2019, the same year NEC's strategic investment arrived. He has led the company through its Series A and B rounds, its climb to unicorn valuation, and its expansion into pharma collaborations with AstraZeneca, MD Anderson and others.
It provides AI-driven molecular and immune profiling of tumors. Its Tumor Portrait test integrates DNA and RNA sequencing with tumor microenvironment analysis to guide cancer treatment decisions and support drug development.
BostonGene was co-founded in 2015 and is led by Andrew Feinberg, its President & CEO since 2019.
A single tumor-normal assay combining genomic and transcriptomic sequencing, biomarkers like tumor mutational burden and PD-L1, and tumor microenvironment subtyping to help oncologists choose therapies for advanced solid tumors.
A $50M strategic investment from NEC in 2019, a $150M Series A led by SoftBank Vision Fund 2 in 2020, and a $150M Series B in 2022 that valued it over $1 billion.
Its main competitors in precision oncology and molecular diagnostics include Tempus AI, Caris Life Sciences, Foundation Medicine, Guardant Health, SOPHiA GENETICS and Personalis.
Explore BostonGene's own channel for platform demos, science explainers and leadership interviews.